66
Registered trials
22
Recruiting
38
Completed trials
40
Sponsors
21
Countries
Phase III:
20
Phase II/III:
3
Phase II:
28
Phase I/II:
10
Phase I (Other):
1
Phase I (FiH):
4
Oversight events:
5 serious breaches
5 temporary halts
3 corrective measures
across 5 trials
View oversight register →
Indications tested
Acute myeloid leukaemia
10
Myelodysplastic syndrome
10
Chronic myelomonocytic leukaemia
2
Non-small cell lung cancer recurrent
1
Non-small cell lung cancer metastatic
1
Systemic mastocytosis
1
Non-small cell lung cancer stage IV
1
Bone marrow failure
1
Non-small cell lung cancer
1
Non-small cell lung cancer stage IIIB
1
Acute myeloid leukaemia (in remission)
1
Myelofibrosis
1
Sponsors using this IMP
AbbVie Deutschland GmbH & Co. KG
5
Groupe Francophone Des Myelodysplasies
5
Celgene Corp.
4
Institut De Recherches Internationales Servier IRIS
3
Syros Pharmaceuticals Inc.
3
Technische Universitat Dresden
3
Ascentage Pharma Group Inc.
2
Centre Hospitalier Regional De Marseille
2
Fondazione Gimema Franco Mandelli Onlus
2
French Innovative Leukemia Organization
2
Hemato-Oncologie voor Volwassenen Nederland (Hovon) Stichting
2
Istituto Romagnolo Per Lo Studio Dei Tumori Dino Amadori IRST S.r.l.
2
All trials
66 totalShowing 1–24 of 66 trials